Department of Pharmacodynamics, Centre for Preclinical Research (CBP), Medical University of Warsaw, 02-097, Warsaw, Poland; Military Institute of Hygiene and Epidemiology, 01-163, Warsaw, Poland.
Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106, Warsaw, Poland.
Eur J Pharmacol. 2021 Aug 5;904:174143. doi: 10.1016/j.ejphar.2021.174143. Epub 2021 May 8.
Disulfiram (DSF) is a well-known anti-alcohol agent that inhibits aldehyde dehydrogenase and results in extreme 'hangover' symptoms when consumed with alcohol. This drug, however, has been suggested as useful in other forms of drug addiction due to its beneficial potential in both drug abuse reduction and withdrawal. However, among other drugs used in alcohol dependence, it carries the greatest risk of pharmacological interactions. Concomitant use of DSF and central nervous system stimulants usually leads to harmful, undesirable effects. To date, there is still limited data regarding the detailed safety profile of DSF as a concomitant drug. In this review article, we outline the current state of knowledge about DSF, its broad pharmacological action, as well as therapeutic effects, with a particular emphasis on the molecular understanding of its potential pharmacodynamic interactions with common addictive substances (e.g., alcohol, cocaine, cannabinoids, opioids) supported by relevant examples.
双硫仑(DSF)是一种众所周知的戒酒药物,可抑制乙醛脱氢酶,当与酒精一起使用时会导致严重的“宿醉”症状。然而,由于其在减少药物滥用和戒断方面的有益潜力,这种药物已被提议用于其他形式的药物成瘾。然而,在其他用于酒精依赖的药物中,它与其他药物相互作用的风险最大。同时使用 DSF 和中枢神经系统兴奋剂通常会导致有害和不良的影响。迄今为止,关于 DSF 作为伴随药物的详细安全性概况的数据仍然有限。在这篇综述文章中,我们概述了 DSF 的当前知识状态,其广泛的药理学作用以及治疗效果,特别强调了其与常见成瘾物质(例如酒精、可卡因、大麻素、阿片类药物)的潜在药效学相互作用的分子理解,同时提供了相关示例。